Market Intelligence, Clinical Progress, and High-Purity Reagents for Complement-Mediated Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CFD drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CFD (Complement Factor D) Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW ~25 kDa. |
View CFD Products |
| Gene Delivery | CFD Lentivirus Premade Particles Full-length ORF for stable cell line generation and overexpression studies. |
View CFD Products |
| Benchmark Ab | Anti-CFD Reference Antibody Recombinant positive control for binding and inhibition assays. |
View CFD Products |
| Validator | CFD siRNA Set For knockdown verification and specificity controls. |
View CFD Products |
| Related Target | Complement Factor B (CFB) Natural substrate of CFD; essential for C3 convertase formation and enzymatic activity assays. |
View CFB Products |
| Related Target | Complement C3 Downstream effector molecule; central to alternative pathway amplification loop. |
View C3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Serine Protease Selectivity Screening | Human CFD plus homolog panel (Trypsin, Chymotrypsin, Elastase, Thrombin) available; Sequence Verified for off-target liability assessment. |
| Enzymatic Activity Validation | High Purity (>95%) CFD + CFB substrate combination; Endotoxin controlled for reliable kinetic assays (Km/Kcat). |
| Cross-species Preclinical Bridging | Human/Mouse/Cynomolgus CFD ortholog proteins with >95% purity for PK/PD and toxicology studies. |
| Alternative Pathway Hemolysis | Active, properly folded CFD required for functional cell-based AP50 assays; Quality controlled for specific activity. |
Live CFD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Complement Factor D therapeutics has entered a critical phase with the recent approval of first-in-class oral inhibitors. The landscape is shifting from paroxysmal nocturnal hemoglobinuria (PNH) toward geographic atrophy (GA) in age-related macular degeneration and rare kidney diseases. As first-generation small molecules establish clinical proof-of-concept, the next wave of R&D is targeting combination regimens with C5 inhibitors and novel modalities including siRNA-based hepatic silencing.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Alexion/AstraZeneca (Danicopan), Roche | PNH, Geographic Atrophy | Selectivity Panel (vs Trypsin/Chymotrypsin); High purity CFD for IC50 determination |
| Peptide Inhibitor | BioCryst (discontinued), Academia | Thrombotic Microangiopathy | Binding Affinity (SPR/BLI); Protease stability assays |
| siRNA/Gene Therapy | Alnylam, Intellia | Complement-mediated diseases | Knockdown validation (siRNA); Lentiviral ORF for rescue experiments |